Furthermore, a detailed study of prostate tumour progression in BRCA2 germline mutation carriers uncovered no LOH in high‐grade prostatic intraepithelial neoplasias, considered precursor lesions to the development of prostate adenocarcinoma, and up to 55% of the malignant tumours analysed (Willems‐Jones et al., 2012). This evidence concerns the gene BRCA2 and cancer.